February 12,Repare AnnouncesRoche has decided to terminate its agreement regarding product line adjustments and external factors, effective May 7, 2024.Camonsertib（RP-3500)Cooperation Agreement, which will regain the global development and commercialization rights of the drug. The agreement was reached in June 2022, with an upfront payment of $125 million and potential milestone payments up to $1.2 billion. As of now,Repare has received a payment of $138.6 million.CamonsertibIs a potential first-in-class oral small molecule ataxia telangiectasia and Rad3-related protein kinase (ATR) inhibitor. Phase I study results showed that, as a single agent,CAmonsertib shows modest efficacy in solid tumors, with a clinical benefit rate (CBR) of 13% and a molecular response rate of 43% among 99 treated patients.Ovarian cancer patients have a relatively good response rate.CBR reached 75%。Repare has also exploredCAmonsertib andPKMYT1(A Synthetic Lethal Target)InhibitorTherapeutic effects of Lunresertib combination.In the preliminary recommendationIIAt the scheduled dose, the overall response rate for all tumor types was33.3%, based onORR according to RECIST criteriaFor50%。Repare is expected to2024The second half of the yearPublishNew Extended QueueData.Currently, there are 14 ATR inhibitors in clinical development globally, among whichCeralasertib (AstraZeneca) is the furthest along, having advanced to Phase III. Impulse Pharma, Zhengda Tianqing, Antengene and other Chinese pharmaceutical companies have also made arrangements, with products still in the early stages of development.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
